• -
69 Results
US Capitol
A Need for Renewed and Cohesive U.S. Policy on Cord Blood Banking
While the Food and Drug Administration currently regulates storage and use of cord blood (CB) in the United States, other state and federal guidelines on CB education, awareness and ethical considerations remain variable, and no mandatory international guidelines exist. To help organize and coordinate efforts across the United States and other nations, policymakers should implement regulations for high quality standards for both private and public CB banks.
Monica M. Matsumoto, Kirstin R.W. Matthews August 4, 2015
A nurse and a patient smile at each other.
Regulating the Therapeutic Translation of Regenerative Medicine
Regenerative medicine and stem cell research are exciting new fields. But as the fields progress toward clinical therapies, controversies emerge. Hype surrounding stem cell research has caused an increase in their use in interventions that are not clinically proven. Furthermore, the regulatory agencies have a lot of difficulty dealing with cell therapies, which are distinctly different from drugs and medical devices they more commonly approve. To move the field forward, advocates, regulators and scientists need to come together to find new options for stem cell research oversight that protects both the patients and the research field.
Maude Rowland Cuchiara, Jackie Olive, Kirstin R.W. Matthews July 6, 2015
Map of Middle East.
Cord Blood Banking in the Arab World: Current Status and Future Developments
In addition to their therapeutic potential, cord blood banks raise ethical and regulatory questions, especially in emerging markets in the Arab world. In this article, the authors review cord blood banking in five countries in the region (Jordan, Saudi Arabia, Egypt, Qatar, and the United Arab Emirates) that were selected for their different CB banking policies and initiatives.
Monica M. Matsumoto, Rana Dajani, Kirstin R.W. Matthews February 13, 2015
Marijuana bud next to a gavel
Marijuana Reform: Fears and Facts
In 1972, a National Commission on Marihuana and Drug Abuse, comprising establishment figures chosen mostly by President Richard Nixon himself, issued a report that declared that “neither the marihuana user nor the drug itself can be said to constitute a danger to public safety” and recommended that Congress and state legislatures decriminalize the use and casual distribution of marijuana and seek means other than prohibition to discourage use. President Nixon ignored the report and Congress declined to consider its recommendations, but during the 40-plus years since its publication, at least 37 states have acted to refashion a crazy-quilt collection of prohibitions, nearly always in the direction favored by the commission. The specifics vary by state, but most reform legislation has followed one of three formulas: decriminalization of marijuana possession, legalization of marijuana for medical use, or legalization of marijuana for adult recreational use. In this issue brief, authors Katharine Neill and William Martin examine the facts and fears surrounding each of these options.
Katharine Neill Harris, William Martin February 4, 2015
blood bags
Cord Blood Banking in the United States: A Public Need for Policy Commitments
Stem cells from umbilical cord blood (CB) can be used to treat over 80 different diseases, including many types of leukemia, lymphoma and inherited immune system disorders. Extensive storage facilities in the United States and around the world collect, test and freeze CB for later use in medical procedures. However, the divide between two different banking models — public versus private — presents policy challenges. This policy report examines the difference between public and private cord blood banks and offers recommendations for US policymakers to improve cord blood banking and ensure high quality standards.
Monica M. Matsumoto, Kirstin R.W. Matthews October 6, 2014